Pharmacogenomics of Asparaginase Induced Hepatotoxicity

This study investigates why some patients with a blood cancer called acute lymphoblastic leukemia (ALL) develop liver damage (hepatotoxicity) from a standard chemotherapy drug called asparaginase, by looking at differences in patients' genes that might explain this reaction. **You may be eligible if...** - You have been newly diagnosed with acute lymphoblastic leukemia (ALL) and have not yet started treatment for it - You are receiving asparaginase as part of your cancer treatment plan - You are able to understand and sign an informed consent form - For retrospective (past patient) enrollment: you received asparaginase between 2012 and 2017 and are a current patient at the University of Southern California **You may NOT be eligible if...** - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.